Poliovirus, illustration. [Thomas Leach/Science Photo Library/Getty Images]
In this week’s episode, we start with news that Fulcrum Therapeutics is scrapping its lead pipeline program for sickle cell disease following concerns from the FDA about the drug’s risks and benefits. Also on the docket, news of Eli Lilly’s latest spending. The pharma giant has added its genetic medicines pipeline and capabilities by signing a $1.9 billion agreement with Ascidian Therapeutics to develop RNA exon editors for treating inherited kidney diseases. Next up, updates to an open-source model for binder design and protein function mapping. Finally, on the peer-review front, we dive into some of the latest vaccine research including insights into the mechanisms that cross-reactive T cells use to target multiple viral species in a single family and an improvement to standard polio vaccines.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
Fulcrum Halts Development of SCD Candidate Pociredir, Sets Strategic Review
By Alex Philippidis and Kevin Davies, PhD, GEN Edge, June 2, 2026
Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases
By Alex Philippidis, GEN Edge, June 3, 2026
Biohub Releases Protein Biology World Model to Address Disease
By Fay Lin, PhD, GEN Edge, May 27, 2026
Cross-Reactive T Cells Could Point to Broad Vaccines or Treatments for Measles, Nipah Virus
GEN, June 2, 2026
Experimental Adjuvant Could Strengthen Mucosal Immunity with Injectable Polio Vaccines
GEN, June 4, 2026
Touching Base Podcast
Hosted by Corinna Singleman, PhD
Behind the Breakthroughs
Hosted by Jonathan D. Grinstein, PhD
Produced with support from:
